| Item Type | Name |
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
|
Academic Article
|
Antifolates: the next generation.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
|
|
Academic Article
|
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression.
|
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
|
Academic Article
|
Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies.
|
|
Academic Article
|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
|
|
Academic Article
|
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
|
|
Academic Article
|
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer.
|
|
Academic Article
|
In response to Dr. Formenti et al. (Int J Radiat Oncol Biol Phys 2005, 63:1275-1276).
|
|
Academic Article
|
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
|
|
Academic Article
|
Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
|
|
Academic Article
|
Phase II trial of temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
|
|
Academic Article
|
Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies.
|
|
Academic Article
|
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
|
|
Academic Article
|
Adjuvant aromatase inhibitors: are we there yet?
|
|
Academic Article
|
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
|
|
Academic Article
|
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
|
|
Academic Article
|
Systemic therapy for advanced or recurrent endometrial carcinoma.
|
|
Academic Article
|
Intraperitoneal chemotherapy for ovarian cancer.
|
|
Academic Article
|
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
|
|
Academic Article
|
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
|
|
Academic Article
|
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
|
|
Academic Article
|
Current treatment of metastatic endometrial cancer.
|
|
Academic Article
|
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
|
|
Academic Article
|
Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.
|
|
Academic Article
|
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
|
|
Academic Article
|
Management of advanced-stage and recurrent endometrial cancer.
|
|
Academic Article
|
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study.
|
|
Academic Article
|
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.
|
|
Academic Article
|
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
|
|
Academic Article
|
Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin.
|
|
Academic Article
|
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
|
|
Academic Article
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
|
|
Academic Article
|
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
|
|
Academic Article
|
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
|
|
Academic Article
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
|
|
Academic Article
|
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
|
|
Academic Article
|
New drugs in ovarian cancer.
|
|
Academic Article
|
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
|
|
Academic Article
|
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
|
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
|
Academic Article
|
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
|
|
Academic Article
|
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
|
|
Academic Article
|
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
|
|
Academic Article
|
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
|
|
Academic Article
|
Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
|
|
Academic Article
|
Current recommendations and recent progress in endometrial cancer.
|
|
Academic Article
|
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
|
|
Academic Article
|
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
|
|
Academic Article
|
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
|
|
Concept
|
Antineoplastic Agents, Immunological
|
|
Academic Article
|
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
|
|
Academic Article
|
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
|
|
Academic Article
|
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.
|